2010 ANNUAL REPORT

Grayson-Jockey Club Research Foundation, Inc.



Research is the pathway to healthier, safer futures for our horses.

The more we discover through research, the better we are at treating disease and preventing injury.

---Dr. Rick Arthur

Grayson-Jockey Club Research Foundation, Inc.

COMMITTED TO THE ADVANCEMENT OF RESEARCH TO ENHANCE THE SAFETY AND HEALTH OF THE HORSE

TABLE OF CONTENTS

Board of Directors & Officers	2
History	3
Review of Activities	6
Research Advisory Committee	8
Research Projects Funded	10
Audited Financial Statements	14
Donors	24
Event Support	29
Members	30

DONOR CLASSIFICATION

	Rokeby Circle		\$10,000 or more annually
	Platinum Circle	STATE OF THE PARTY OF	\$7,500 or more annually
	Gold Circle		\$5,000 or more annually
	Silver Circle		\$2,000 or more annually
	Patron		\$1,000 or more annually
	Supporting		\$500 or more annually
	Sustaining		\$200 or more annually
١	Annual	1	\$100 or more annually

Board of Directors



Dell Hancock Chairman



A. Gary Lavin, VMD Vice Chairman

Rick Arthur, DVM William M. Backer Larry R. Bramlage, DVM

Charlsie Cantey

Adele B. Dilschneider

Donald Dizney

William S. Farish Jr.

John K. Goodman

Lucy Young Hamilton

Joseph W. Harper

Kevin Lavin

Braxton Jones Lynch

Leverett Miller

John M. B. O'Connor

John C. Oxley

Ogden Mills Phipps

Hiram C. Polk, MD

Daisy Phipps Pulito

Geoffrey Russell

Joseph V. Shields Jr.

Jack Robbins, DVM Director Emeritus

Officers & Staff



Edward L. Bowen President



Nancy C. Kelly Vice President of Development; Secretary

Laura Barillaro

Treasurer

Jenifer Van Deinse Assistant Director of Development

Resia L. Ayres Operations Administrator

John Mac Smith, DVM Veterinary Consultant

History

Memory of a distinguished American was honored in 1940 when the original Grayson Foundation was formed. Admiral Cary Grayson had been best known as the personal physician to President Woodrow Wilson, and at the time of his death, in 1938, he was chairman of the American Red Cross. He was also a racing man, whose best horses included My Own, winner of the Saratoga Cup, Saratoga Handicap, and Maryland Handicap.

On occasion, Admiral Grayson was able to combine his medical profession with his other interests. One such occasion was a spring day in 1919, when, upon Admiral Grayson's suggestion, President and Mrs. Wilson took a break from the Versailles Treaty negotiations and drove out to join Lord Derby for a day at the races at Longchamp.

Admiral Grayson owned Blue Ridge Farm in Virginia, which is continued today by grandchildren. After the death of Admiral Grayson, the \$2,500 Grayson Stakes was inaugurated at Laurel. Matt Smart, who had been training for Grayson at the time of his death, sent out the winner in Houghton P. Metcalf's High Velocity. The 1 1/2-mile Grayson Stakes was run annually through 1949, and subsequent winners included Heelfly, Pilaster, and Double Brandy.

Admiral Grayson was connected to some of the formulative stages which led eventually to the

establishment of the equine research foundation named for him. He was president of an organization called the Gargas Foundation, and he asked its director, Dr. Herbert Clark, to help advise the American Thoroughbred Breeders Association ("ATBA"). The breeders organization in the late 1930s was exploring various ways to address the promotion of research for horses.

By 1939, a plan had been formulated whereby the ATBA would launch a campaign to raise \$100,000 and, once that amount had been pledged, the Grayson Foundation would become a reality. The Jockey Club, under direction of its chairman, William Woodward Sr., was among the initial respondents, pledging 20 percent of the total.

The Grayson Foundation became a reality in 1940, and its initial incorporators included Woodward, while John Hay (Jock) Whitney was the Foundation's initial president. The first grant was made before the year was over, a \$1,000 donation to the University of Pennsylvania Veterinary School to continue its work on periodic ophthalmia. In 1940, the horse and mule were still deeply involved in military defense, and the scope of the Foundation's efforts went far beyond the Thoroughbred, to all breeds, although the impetus came from leaders in Thoroughbred racing.

History

From the beginning, the aim was to support research at existing institutions through funding rather than carry out the research itself. A statement by Woodward read in part that the formation of the Foundation is "the result of the conviction of a large number of persons devoted to the raising and breeding of horses that there is a positive need for further research in veterinary medicine and in the breeding, raising, and handling of horses." Over nearly a half-century, the Grayson Foundation operated as a separate entity, fulfilling the purposes of its founders despite constant limitations on available funding.

For much of its history, the Foundation sought to disperse \$100,000 annually in grants to specific research projects. Its success in this goal resulted in support for a number of projects which represented steps forward, among them being development of vaccines against Equine Viral Arteritis and herpesvirus infections, determining causes of viral abortions leading to development of the most effective vaccine yet developed, and influencing estrous cycles in mares to increase fertility. The Jockey Club created a research foundation in 1984, and five years later this was merged with Grayson, to be known since then as the Grayson-Jockey Club Research Foundation, Inc. (GJCRF). Grayson had a half-century

background in research matters, and The Jockey Club had more wherewithal financially, so the annual allocation for research could be increased, and that pattern has continued in many years since then.

During the 1990s, three gifts of remarkable generosity were instrumental in enhancing the success of the Foundation in fulfilling its mission. In 1991, the Robert J. Kleberg and Helen C. Kleberg Foundation donated \$2 million to Grayson-Jockey Club Research Foundation. Mr. Kleberg had studied genetics and as head of King Ranch developed the Santa Gertrudis breed of cattle. He also was instrumental in development of the American Quarter Horse, and the many excellent Thoroughbreds he bred included 1946 Triple Crown winner Assault.

In 1993, the Foundation received another major gift when Paul Mellon donated the \$1 million bonus that his Kentucky Derby winner Sea Hero won in the Chrysler Triple Crown Challenge. Mr. Mellon requested that double that amount be raised in response, and this endowment drive was successfully concluded during the 1995-96 fiscal year. The \$1 million was double matched, as members of The Jockey Club and other contributors donated a total of more than \$2 million. Mr. Mellon passed away in 1999, leaving \$2.5 million to the Foundation's endowment. In 2000, the Foundation created the Rokeby Circle as the designation of those who contribute \$10,000 or more in a given year. Rokeby is the name of Mr. Mellon's beloved Virginia estate, where he bred the champions Mill Reef, Arts and Letters, Fort Marcy, and Key to the Mint.

History

The Sea Hero Triple Crown bonus, and resultant endowment drive, helped attain one of the other goals set by chairman John Hettinger, i.e., raising the Foundation's net assets to the \$10-million level. Under the current chairman, Dell Hancock, growth continued, and net assets stood at \$19.5 million at the conclusion of 2010.

One key stimulus was the Oxley Challenge, initiated in 2004. Under the direction of Foundation board member John C. Oxley, his family's Oxley Foundation pledged \$1 million over four years contingent on the Foundation raising a like amount in other new income sources. The Foundation was successful in that match, and so received \$250,000 from the Oxley Foundation in each of four years.

In 1999, under direction of Drs. Gary Lavin and Larry Bramlage, the Foundation's process of evaluating grants was reorganized. Instead of having separate committees of academicians and practicing veterinarians, a single Research Advisory Committee ("RAC") was created. The Committee includes 32 individuals representing various research specialties and veterinary practices from across North America. Each year, the committee is convened in January, having read all proposals submitted by the research community. The RAC spends three days pouring over the projects and rates them top to bottom, recommending the best to the board of directors. The board then meets to determine how many projects can be funded in that year.

Dr. Bramlage was the original chairman of the RAC and remained in that post until he chose to step aside in 2009. He was succeeded by Dr. Paul Lunn of Colorado State University.

In 2006, in collaboration with The Jockey Club, the Foundation coordinated and underwrote the first Welfare and Safety of the Racehorse Summit ("Summit") hosted by Keeneland. That meeting, and a second gathering of industry experts in 2008, generated a number of recommendations which the industry has embraced to a large extent. The Jockey Club's Thoroughbred Safety Committee endorsed recommendations of the Summit, and the National Thoroughbred Racing Association's race track accreditation program is based in part on those recommendations. Also, the Summit helped organize the Equine Injury DatabaseTM which is designed to provide the industry much needed epidemiological analysis of trends, aimed at improving injury rates nationally. The third Summit was held in 2010.

Since 1983, Grayson-Jockey Club has individually provided more than \$18.1 million to fund 279 projects at 40 universities in North America and overseas.

Review of Activities

GRANT AWARDS

Grayson-Jockey Club Research Foundation ("GJCRF," the "Foundation") provided \$934,304 to fund 19 projects approved by the board of directors in 2010.

The projects funded include Dr. Jeffrey Thomason's project on Track Banking and Asymmetry of Hoof Loading at the University of Guelph. This project was selected as recipient of the Elastikon™ Equine Research Award for 2010. The project is supported in part by a donation to the Foundation from Johnson & Johnson's Consumer Products Division, manufacturer of Elastikon™ tape and other equine products.

The 2010 Storm Cat Career Development Award went to Catherine H. (Radcliffe) Hackett, a post-doctoral fellow at Cornell University. Dr. Hackett worked with Dr. Lisa Fortier and Dr. Julia Flaminio on the project entitled, "Temporal Analysis of Megenchymal Progenitor Cells."

This was the fifth annual Storm Cat Career Development Award which totals \$15,000. Funded by board member Lucy Young Hamilton, the Storm Cat Award is designed to give support to a potential career equine research candidate. It is named for the champion stallion Storm Cat, which stood at Mrs. Hamilton's family farm, Overbrook. The award was initiated in 2006, and its first four recipients subsequently were employed in research positions at major universities.

National Thoroughbred Racing Association ("NTRA") Charities' Barbaro Memorial Fund had asked the Foundation in 2007 to evaluate and recommend projects on laminitis that would be funded through the Barbaro fund. The fund was named in honor of the 2006 Kentucky Derby winner which succumbed to laminitis after valiant efforts had

been made to save him following his injury in the Preakness. NTRA continued this colaberation funding two projects in 2010: Dr. Dean Richardson of the University of Pennsylvania and Dr. Nicholas Franks of the University of Tennessee.

WELFARE & SAFETY SUMMIT

The third Welfare and Safety of the Racehorse Summit, was held in Lexington, Kentucky, on June 28 and 29. Underwritten by Grayson-Jockey Club Research Foundation and The Jockey Club and hosted by Keeneland, it facilitated discussion of implementation strategies to improve conditions in various facets of the Thoroughbred industry. The Summit concluded with the development of objectives in four areas:

Racing Equipment and Safety

- Process for implementing and tracking standards for racing equipment
- Implementation of advanced safety equipment on a phased basis based on data
- Safety committees at all tracks to focus on licensing, experience and post-meet lessons

Racetrack Environment and Training Practices

- Formalize reciprocity of veterinarians', stewards', and starters' lists nationally
- · Develop best practices documents for
 - Training practices
- Stable area design
- Track maintenance
- Biosecurity / disaster planning
- Develop comprehensive database
 - Track maintenance
 - Training records (including injuries)
 - Vet records
- Re-evaluate traditional practices
 - Veterinary services
 - Racing office operation / condition book
- Restructure claiming regulations

Review of Activities

Education, Licensing and Continuing Education

- Create an advisory committee to address and determine content for continuing education as means toward accreditation for trainers, grooms, farriers and jockeys
- Endorse a National Trainers Test; find a means to validate the test with a group such as an educational testing service

<u>Transitioning Thoroughbred Racehorses to</u> <u>Second Careers</u>

The NTRA was invited to participate, and its transitioning committee addressed the following:

- Establish Standing Committee
- Create track liaison position at each racetrack
- Publish best practices guidelines: funding, vet care, communications, education, strategies to give incentive for transition to second career
- Cooperate with AAEP (American Association of Equine Practioners) to create a vet guideline classifying racing conditions for horses' transition into second careers
- Establish accreditation program for rescues

The Summit concluded with a panel discussion concerning implementation of safety and soundness recommendations, moderated by Jim Gagliano, president and chief operating officer of The Jockey Club.

FUND RAISING

The Foundation benefited from the loyalty and generosity of its donor base while continuing its outreach to new donors. Unrestricted contributions and membership dues for core mission research totaled \$859,471, down from the comparable total of \$868,601 in 2009.

In May the "Ride for Research" was held at Vera Earl Ranch in Sonoita, Arizonia. This annual event is hosted at various ranches in Arizonia each spring and co-ordinated by Mr. John Goodman.

Under the direction of Mrs. Nancy Kelly, vice president of development, several successful fund raising events were held during 2010. In June the 2010 Belmont Bash was held at The Garden City Hotel in Garden City, New York. This event benefited the B.E.S.T. (Backstretch Employee Services Team) as well as the Foundation. The Elizabeth Locke Jewels Trunk Show to Benefit Equine Research was held in August in Saratoga Springs, New York. Also held later in the month was the Tenth Annual NYRA (New York Racing Association) Charity Golf Tournament at the Saratoga National Golf Club.

Research Advisory Committee

The Research Advisory Committee evaluates research proposals and advises the Foundation's Board of Directors on the basis of the needs of the industry and scientific quality of each project.

For the 2010 grants allocation,

the committee was comprised of the following persons who served the Foundation without compensation:

CHAIRMAN

Paul Lunn, DVM

Professor & Head of Clinical Sciences- College of Vet. Medicine Colorado State University

Fort Collins, Colorado

Graduate - University of Liverpool, England

Jay Addison, SVM

Private Practice

Independence, Louisiana

Graduate - Louisiana State University

Jill Beech, VMD, DACVIM

Professor, Medicine & Reproduction

University of Pennsylvania

Kennett Square, Pennsylvania

Graduate - University of Pennsylvania

Hugh B. Behling, DVM

Private Practice, Performance

Simpsonville, Kentucky

Graduate - Washington State University

Jeff A. Blea, DVM

Race Track Practice, Managing Partner

Von Bluecher, Prida, Blea Inc.

Pasadena, California

Graduate - Colorado State University

Steve Brinsko, DVM

Professor, College of Veterinary Medicine

Texas A & M University

College Station, Texas

Graduate - Texas A & M University

Tom Brokken, DVM

Partner

Teigland, Franklin & Brokken DVM's PA

Fort Lauderdale, Florida

Graduate - University of Minnesota

Claire Card, DVM, PhD, DACT

Professor, Theriogenology

Western College of Veterinary Medicine

Saskatchewan, Canada

Graduate - Cornell University

Thomas Chambers, DVM

Professor

University of Kentucky - Gluck Center

Lexington, Kentucky

Graduate - University of Notre Dame

Carol Clark, DVM

Private Practice

Peterson & Smith Equine

Ocala, Florida

Graduate - Texas A & M University

Barry David, VMD, PhD, DACVIM

Professor, College of Veterinary Medicine

Texas A & M University

College Station, Texas

Graduate - University of Pennsylvania

Frederik J. Derksen, DVM, PhD, ACVIM

Professor, Department of Large Animal Sciences

Michigan State University

East Lansing, Michigan

Graduate - Ontario Veterinary College

Julia Felippe, DVM, MS, PhD

Professor, Large Animal Medicine

Cornell University

Ithaca, New York

Graduate - Kansas State University

Lisa Fortier, DVM, PhD, DACVS

Associate Professor, Large Animal Surgery

Cornell University

Ithaca, New York

Graduate - Colorado State University

Grant Frazer, BVSc, MS, Dip. ACT, MBA

Director, Veterinary Teaching Hospital

The Ohio State University

Columbus, Ohio

Graduate - University of Queensland, Australia

David A. Freeman, MVB, MRCVS, PhD, DACVS

Professor, Chief Large Animal Surgery

University of Florida

Gainesville, Florida

Graduate - University of Dublin, Ireland

John Hubbell, DVM, MS, DACVA

Professor

The Ohio State University

Columbus, Ohio

Graduate - The Ohio State University

Research Advisory Committee

L. Chip Johnson, DVM

Private Practice

Florida and New Jersey

Graduate - Louisiana State University

Doug Koch, DVM

Retired Race Track Practice

Owner Berkshire Stud

Pine Plains, New York

Graduate - University of Illinois, Urbana

A. Gary Lavin, VMD

Private Practitioner

Goshen, Kentucky

Graduate - University of Pennsylvania

Mark D. Markel, DVM, PhD

Professor & Chair, Department of Medical Sciences

Associate Dean for Advancement

School of Vet. Med., University of Wisconsin-Madison

Madison, Wisconsin

Graduate - University of California-Davis

Paul Morley, DVM, PhD, DACVIM

Professor, College of Veterinary Medicine

Colorado State University

Fort Collins, Colorado

Graduate - Washington State University

Dean Nealy, VMD, PhD, DACT

Director, Equine Reproductive Unit

Mid-Atlantic Equine

Lambertville, New Jersey

Graduate - University of Pennsylvania

Dale Paccamonti, DVM, MS, DACT

Professor of Theriogenology

Louisiana State University

Baton Rouge, Louisiana

Graduate - Michigan State University

Scott Palmer, VMD, DABVPCEP

Owner

New Jersey Equine Clinic

Clarksburg, New Jersey

Graduate - University of Pennsylvania

Dean Richardson, DVM, DACVS

Charles W. Raker Professor of Equine Surgery

Chief, Large Animal Surgery

New Bolton Center, University of Pennsylvania

New Bolton, Pennsylvania

Graduate - The Ohio State University

Thomas Riddle, DVM

Owner

Rood and Riddle Equine Hospital

Lexington, Kentucky

Graduate - University of Georgia

Bonnie Rush, DVM, MS, DACVIM

Department Head, Clinical Sciences

Equine Internal Medicine

Kansas State University

Manhattan, Kansas

Graduate - The Ohio State University

L. Chris Sanchez, DVM, PhD, DACVIM

Assistant Professor, Large Animal Medicine

University of Florida

Gainesville, Florida

Graduate - University of Florida

Mary Scollay, DVM

Equine Medical Director

Kentucky Horse Racing Commission / University of Kentucky

Lexington, Kentucky

Graduate - University of Illinois

Nathan Slovis, DVM, Dip., ACVIM, CHT

Director, McGee Medical Institute

Hagyard Equine Medical Institute

Lexington, Kentucky

Graduate - Purdue University

John Stick, DVM, DACVS

Professor & Chief of Staff

Department of Large Animal Sciences

Michigan State College of Veterinary Medicine

East Lansing, Michigan

Graduate - The Ohio State University

CONSULTANT

Johnny Mac Smith, DVM

Founding Partner

Peterson & Smith Equine Hospital

Ocala, Florida

Graduate - Auburn University

Race Surface Optimization for Fetlock Injury Prevention (II)

Drs. Sue Stover & Mont Hubbard, University of California-Davis

This is the logical extension of a one-year grant funded last year in which the use of a 4 x 4 foot box was utilized to duplicate the make-up of race track surfaces. The question of the first project was whether this process could be validated, and early indications are that it was a success. The next step continues the process. The composite review from the Research Advisory Committee included the comment that continuing along this path could eventually "allow evaluation of literally hundreds of racetrack surface characteristics to better optimize their material properties."

Ethyl Pyruvate and Endotoxemia in Horses Dr. Sue Holcombe, *Michigan State University*

Endotoxemia is a common cause of death in serious equine conditions such as colitis, strangulating intestinal obstructions, and septicemia. Available treatments are not consistently successful, and finding a clinically useful treatment, without side effects, remains an important goal. That is the basis for this project, which will test whether ethyl pyruvate is a useful medication. It has been shown to ameliorate intestinal, cardiac, and other conditions in humans and other species. In humans, it has been found to be effective in critical illness even after the problem has become acute. Further, it has already been shown to be safe for horses. The investigator hopes to demonstrate that ethyl pyruvate treatment will be more effective than flunixin meglumine, and it would also be considerably less expensive.

In Vivo Gene Transfer for the Treatment of Laminitis

Dr. Dean Richardson, University of Pennsylvania

This project seeks to develop a gene therapy approach to prevent laminitis in the contralateral hoof when a horse is being treated for a musculoskeletal injury. This, of course, was what eventually ended the efforts to save Barbaro and is a frequent threat to horses with hoof and leg injuries. The well known research team

already has compelling preliminary data which encourages the hypothesis that use of recombinant adeno-associated viruses can be used as vectors to deliver a therapeutic gene (TMP-3) to the lamellar tissues. This is meant to inhibit the damage to the epidermal laminae without disrupting the normal hoof structure.

Factors Associated with Success and Failure Dr. Keith Betteridge, *University of Guelph*

Pregnancy loss during the third week of gestation is a major problem in horses. Reviewers regarded it likely that this project will provide greater understanding of the interaction of the conceptus and the endometrium at that time of gestation. The probable understanding of proteins associated with early pregnancy loss will help in understanding mechanisms involved in both successful and failed pregnancies, and suggest possible methods of therapy. The techniques employed will include comparison of the transcriptomes of endometrium and trophoblast in successful and unsuccessful pregnancies, characterizing the influences of prostaglandin, and identifying factors produced by the fetus that correlate with the processes of its immobilization. The researchers will examine gene expression of associated proteins, etc., in normal and failed pregnancies to search for markers of early embryonic loss.

Mechanisms of Pulmonary Vein Remodeling in EIPH Dr. Fred Derksen, Michigan State University

This is the next step in a sequence of projects undertaken by Dr. Derksen, some funded by the Foundation. This research team has discovered scarring around blood vessels in the lungs of horses affected with Exercise Induced Pulmonary Hemorrhage (EIPH). It is believed that the scarring obstructs the veins, causing blood to back up in the lung and rupture its fragile small blood vessels. The main goal of this next study is to determine why the scarring occurs, by studying changes in molecules in vein walls that occur in response to exercise, both in non-EIPH horses and EIPH horses. Understanding EIPH pathology in general and the vein scarring in particular is described as necessary before the ultimate goal of prevention or effective treatment could be achieved.

Systemic Effects of Analgesic Combinations in Horses Dr. Chris Sanchez, *University of Florida*

Management of pain is a key element in veterinary care of horses, especially those with colic or lameness. In addition to the humane urge to protect the animal from pain, there is a case management element in that the pain is often accompanied by severe inflammation that can lead to organ failure and founder. Many pain killers, however, have negative side effects including stomach ulcers, diarrhea, and kidney failure, so that seeking better pain killers is an important subject for research. This project will test lidocaine, ketamine, and butrophanol, individually, and in combinations not only for their pain killing properties but to verify that they have no adverse side effects on behavior, heart rate, respiratory rate, gastrointestinal function, or the immune system. The study is predicated on the belief that none of those ill effects will be manifested.

Endotoxemia as a Predisposing Factor for Laminitis Dr. Nicholas Frank, *University of Tennessee*

There exists considerable circumstantial evidence that there is a relationship between endotoxin and onset of laminitis. This project seeks to verify that causal relationship and, if it successfully does so, would also verify that use of anti-inflammatories has a valid scientific basis.

Rapid PCR Diagnosis of Equine Botulism Types A, B, and C

Dr. Raymond Sweeney, University of Pennsylvania

Botulism occurs throughout North America and in any given year some cases can be expected. When it does strike, it can spread quickly, and last year one outbreak caused the death of 100 horses. Surviving botulism depends on rapid diagnosis, followed by antitoxin administration. One of the difficulties in managing botulism outbreaks is that the traditional diagnostic test requires two to three weeks. The goal here is to develop a test that can verify the disease much more rapidly. The Foundation funded this research team previously, and they have made major progress in developing a polymerase chain reaction (PCR) test for botulism type B. This work will continue that effort and extend to types A and C. The research capitalizes on recent progress in detection of botulism in humans, driven by the disease's potential as a bioterrorism threat.

Clinical Administration of Doxycycline for Arthritis Dr. Lisa Fortier, Cornell University

Arthritis is a common problem in horses. Treatments are divided between those that alleviate pain and those that preserve joint cartilage, but there is need for additional, easily administered oral treatments to halt the progression of arthritis. Doxycycline belongs to the tetracycline family of antibiotics and is typically used in horses to treat Lyme disease. It is believed to have potential in alleviating arthritis because it is a potent inhibitor of enzymes called matrix metalloproteinases (MMPs). MMPs are responsible for degrading cartilage in joints, leading to arthritis. The MMP-inhibiting effects of doxycycline can be achieved at concentrations far lower than those required to kill bacteria. One aspect of this study will be to determine a minimal dosing level to treat arthritis, one that is not antibacterial and thus would have no potential for contributing to drug-resistant bacteria. It is anticipated that if doxycycline is verified as useful treatment against arthritis, it can be easily administered by lay persons.

Toxins TCD A & B of Clostridium Difficile for Horse Immunization

Dr. Sergey Artiushin, University of Kentucky

Clostridium difficile is a bacteria that multiplies in the intestines of horses and other mammals when normal bacterial flora is poorly developed or becomes disrupted. Two very large and potent toxins are released by Clostridium difficile, causing massive damage to the intestinal lining. The resulting enterocolitis is an important component of the neonatal diarrhea complex. There currently is no vaccine, and treatment is expensive. This project seeks to generate antibodies in the horse to the parts of each toxin that bind to intestinal cells and thus block entry of the toxin. The work will involve cloning of polypetides of toxins A and B, using recombinant DNA technology. Success should lead to a vaccine that could be administered to mares two months before foaling. The vaccine would provide colostral antibodies to the newborn foal. The approach is similar to that already in use to generate colostral antibodies to a different Clostridium-connected toxin that causes colitis in newborn foals.

Track Banking and the Asymmetry of Hoof Loading Dr. Jeffrey Thomason, *University of Guelph*

With every stride at racing speed, forces acting on the legs reach as high as two to three times the horse's body weight. Avoiding any increased loading is intuitively regarded as beneficial in preventing injury. It is believed in theory that having no banking on the turns or too-low banking can increase the forces, but little scientific work on banking has been done since Swedish studies on Standardbred horses in the 1970s. This study aims to refocus attention on developing insight into the effects of different banking, by use of strain gauges. Additionally, the study will address the widespread practice of racing and training almost exclusively counter-clockwise in North America. Horses will be exercised in both directions and measurements will be recorded as to strains on different parts of the hoof in both directions.

Orthopedic and Genetic Roles in Wobbler Syndrome Dr. James MacLeod, *University of Kentucky*

Wobbler Syndrome carries a guarded to poor prognosis, and many afflicted horses are not good candidates for vertebral fusion and have to be euthanized. The focus of this project will be to examine the role of abnormal bone and cartilage formation in the neck vertebrae, and to identify regions of DNA and, potentially, even specific genes that are involved in Wobbler Syndrome. Technology will include three-dimensional X ray, Magnetic Resonance Imaging, and DNA isolation. Variation in the DNA nucleotide sequence of more than 54,000 positions across the genome will be compared between horses afflicted and control-group horses. This study is intended to add to existing understanding of the cause and progression of Wobbler Syndrome and lead to improved management and therapeutic practices.

Molecular Characterization of Neurovirulent Equine Herpevirus-1 Strains

Dr. Udeni Balasuriya, University of Kentucky

The increased incidence of the neurologic form of Equine Herpevirus-1 has caused highly publicized problems at race tracks, farms, and other equine centers in recent years. The Foundation has

supported several projects on EHV-1, and this lab has discovered there are more types of mutations than were previously thought, which have impact on the prevalence of the neurologic strain of the disease. Further complicating the issue is the discovery that some horses showed the neurologic signs but did not have the predicted mutated forms of the virus. This project will attempt to identify further additional reputed neurovirulence determinants of EHV-1 by sequencing genes essential for replication. The researchers will utilize the unique situation at the University of Kentucky, where an extensive collection of EHV-1 isolates has been collected over many years.

Pharmacokinetics/Pharmacodynamics of Quinapril in Horses

Dr. Jennifer Davis, North Carolina State University

Antigen converting enzyme (ACE) inhibitors are frequently used in human medicine and small animal veterinary medicine to treat heart failure, chronic renal disease, and high blood pressure. One ACE inhibitor, enalapril, has been studied in horses but found ineffective when given orally. (Oral formulation is important because horses need to stay on the drug for a prolonged period.) This project will test whether another ACE inhibitor, Quinapril, is effectively absorbed by the horse's gastrointestinal tract. It has been shown to improve heart function of horses with valvular disease and atrial fibrillation, but is not yet widely used in horses because the absorption and pharmacological effects in the species have not yet been adequately studied. This project is aimed at answering that question and, if the results are positive, to calculate the appropriate dose to achieve beneficial effect. The researchers further raise the suggestion that Quinapril might also prove to be beneficial in the treatment of laminitis and heaves.

Equine Bone Regeneration with Adult Stem Cells Dr. Mandi Lopez, Louisiana State University

Adult stem cells in recent years have been the subjects of research to determine their potential to treat injuries in horses. Bone repair is one aspect which is being investigated. It requires about 70 million adult stem cells to repair a single cubic centimeter of bone.

Only two types of tissues in mammals have been shown to have the potential to provide that many stem cells, i. e., adipose (fat) and bone marrow. The laboratory of this researcher has found that stem cells from both sources indicate the ability to form bone in cell experiments. Comparisons on the bone-forming abilities of fat-derived and bone-marrow-derived stem cells have not been done conclusively, and this project will address that important next question. The researchers believe that "results from this study will significantly advance treatment of broken bones in the horse."

CONTINUING PROJECTS FROM 2009

Antiviral Drugs To Combat Equine Herpes Virus-1 Infection

Dr. Arthur Frampton, University of N. Carolina-Wilmington

Equine herpes virus-1 continues to be a major problem, which can result in paralysis and, in the case of pregnant mares, abortion. While a number of research projects on EHV-1 are ongoing, there is not an effective vaccine which is long lasting, so horses are subjected to repeated vaccination. This proposal seeks a solution other than vaccination, i. e., that a better approach might be surveillance and health monitoring coupled with antiviral drugs after EHV-1 infection. This approach would seek to lessen significantly the possibility of an infected horse becoming paralyzed or aborting. Many horses recover from EHV-1, and the treatment protocol suggested here could be expected to improve that rate.

Prevention Of Equine Herpes Virus-1 Myeloencephalitis By Delayed Therapy Dr. Lara Maxwell, Oklahoma State University

This study will seek to determine whether drug therapy can be effective if applied in barns where equine herpes virus-1 has gone unidentified until horses are in the latter stages of infections. At that stage of infection, neurological disease can be expected to develop within a few days.

This research team has found that the antiviral drug valacyclovir is effective if administered early in the course of the infection, and this new project could be important in protecting horses from developing crippling disease and also reducing the contagious period of the infection.

Developing Equine Bone Morphogenetic Protein For Cartilage And Bone Repair

Dr. Matthew Stewart, *University of Illinois* at Urbana Champagne

Bone morphogenetic protein 2 has been effective in human medicine for fracture repair and spinal fusions. This project seeks to develop an equine BMP-2 gene therapeutic reagent and demonstrate that it can be applied to stimulate accelerated bone formation and cartilage repair. Another researcher in this field, Dr. Mark Markel, recently noted that "there are currently no groups producing sufficient quantities of equine BMP-2 necessary for clinical applications." The above project could help fill that need.

Effect of Digital Hypothermia on Inflammatory Injury in Laminitis

Dr. James K. Belknap, The Ohio State University

The same inflammatory mechanisms that lead to organ failure in human sepsis/systemic infections are also present in the equine lamina in the early stages of laminar failure. The researchers propose to assess the efficacy of digital hypothermia in inhibiting the early inflammatory events likely to lead to laminar failure. Hypothermia in human-related medical studies has been demonstrated to decrease multiple facets of the inflammatory process. The advantage in the horse is that it can be applied locally to the lower limbs, and thus not affect the entire body's immune response to infection. If the therapy is found to be effective at inhibiting some of the inflammatory signaling, it will allow the researcher and practitioner to address additional pathologic mechanisms known to also be taking place during laminar injury.

Independent Auditors' Report

Board of Directors Grayson-Jockey Club Research Foundation, Inc. New York, New York

We have audited the accompanying statement of financial position of the Grayson-Jockey Club Research Foundation, Inc. (the "Foundation") as of December 31, 2010, and the related statements of activities and cash flows for the year then ended. These financial statements are the responsibility of the Foundation's management. Our responsibility is to express an opinion on these financial statements based on our audit. The financial statements of the Foundation as of December 31, 2009, were audited by other auditors whose report dated June 2, 2010, expressed an unqualified opinion on those statements.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Foundation as of December 31, 2010, and the changes in its net assets and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

As discussed in Note 2 to the financial statements, the Foundation adopted Accounting Standards Codification 958, Section 205, *Reporting Endowment Funds*, as of January 1, 2010 for classification of donor-restricted endowment funds.

Crowe Horwath LLP

Crown Horwath UP

New York, New York

June 2, 2011

Statements of Financial Position

DECEMBER 31, 2010 AND 2009

	2010	-	2009
ASSETS			
Cash and cash equivalents	\$ 629,099	\$	575,106
Investments at fair value	18,754,811		17,171,195
Contributions receivable	52,985		67,749
Other receivables	47,203		96,797
Prepaid expenses	6,700		4,480
Inventory	1,890		2,760
Fixed assets at cost, less accumulated depreciation	 1,278		347
	\$ 19,493,966	\$	17,918,434
LIABILITIES AND NET ASSETS			
Liabilities			
Accounts payable and accrued liabilities	\$ 65,778	\$	68,817
Accounts payable and accrued liabilities Net Assets	\$ 65,778	\$	68,817
•	\$ 65,778	\$	68,817
Net Assets	\$	\$	
Net Assets Unrestricted	\$ 11,566,216	\$	10,620,170
Net Assets Unrestricted Temporarily restricted	\$ 11,566,216 1,952,687	\$	10,620,170 33,829

See accompanying notes to financial statements.

Statement of Activities

FOR THE YEAR ENDED DECEMBER 31, 2010

Proceeds from fund raisers, net of direct benefit costs of \$175,887	1		nrestricted		mporarily estricted	ermanently Restricted	Total
Proceeds from fund raisers, net of direct benefit costs of \$175,887 188,803 - 188,8 Investment income 197,237 135,197 - 332,4 Net realized and unrealized gains on investments 929,971 641,354 - 1,571,3 Other 1,664 - - 1,6 Net assets released from restrictions 734,590 (734,590) - - Total revenue 2,912,006 632,525 - 3,544,5 Expenditures 453,133 - - 453,1 Grants 934,304 - - 934,3 Grants - EDRI 453,133 - - 453,1 Professional fees 393,484 - 393,4 Travel and meetings 60,305 - - 60,3 Investment fees 43,514 - - 43,5 Seminars and summits 26,493 - - 26,4 General and administrative expenses 54,727 - 54,7 Total expenditures 1,965,960 - - 1,965,9 Change in net assets before effect of new accounting pronouncement 946,046 632,525 - 1,578,5 Total expendition pronouncement 946,046 632,525 - 1,578,5 Total expenditure pronouncement 946,046 632,525 - 1,578,5	Revenue			-			
benefit costs of \$175,887 188,803 - - 188,8 Investment income 197,237 135,197 - 332,4 Net realized and unrealized gains on investments 929,971 641,354 - 1,571,3 Other 1,664 - - 1,6 Net assets released from restrictions 734,590 (734,590) - - Total revenue 2,912,006 632,525 - 3,544,5 Expenditures Grants 934,304 - - 934,3 Grants - EDRI 453,133 - - 453,1 Professional fees 393,484 - - 393,4 Travel and meetings 60,305 - - 60,3 Investment fees 43,514 - - 43,5 Seminars and summits 26,493 - - 54,7 Total expenditures 1,965,960 - - 1,965,9 Change in net assets before effect of new accounting pronouncement 946,046 632,525 - 1,578,5	Contributions and membership dues	\$	859,741	\$	590,564	\$ -	\$ 1,450,305
Investment income 197,237 135,197 - 332,4	Proceeds from fund raisers, net of direct						
Net realized and unrealized gains on investments 929,971 641,354 - 1,571,3 Other 1,664 - - 1,6 Net assets released from restrictions 734,590 (734,590) - - Total revenue 2,912,006 632,525 - 3,544,5 Expenditures Grants 934,304 - - 934,3 Grants - EDRI 453,133 - - 453,1 Professional fees 393,484 - - 393,4 Travel and meetings 60,305 - - 60,3 Investment fees 43,514 - - 43,5 Seminars and summits 26,493 - - 26,4 General and administrative expenses 54,727 - - 54,7 Total expenditures 1,965,960 - - 1,965,96 Change in net assets before effect 946,046 632,525 - 1,578,5	benefit costs of \$175,887		188,803		-	-	188,803
investments 929,971 641,354 - 1,571,3 Other 1,664 - - 1,6 Net assets released from restrictions 734,590 (734,590) - - Total revenue 2,912,006 632,525 - 3,544,5 Expenditures Grants 934,304 - - 934,3 Grants - EDRI 453,133 - - 453,1 Professional fees 393,484 - - 393,4 Travel and meetings 60,305 - - 60,3 Investment fees 43,514 - - 43,5 Seminars and summits 26,493 - - 54,7 Total expenditures 1,965,960 - - 1,965,9 Change in net assets before effect of new accounting pronouncement 946,046 632,525 - 1,578,5	Investment income		197,237		135,197	-	332,434
Other 1,664 - - 1,6 Net assets released from restrictions 734,590 (734,590) - - Total revenue 2,912,006 632,525 - 3,544,5 Expenditures Grants 934,304 - - 934,3 Grants - EDRI 453,133 - - 453,1 Professional fees 393,484 - - 393,4 Travel and meetings 60,305 - - 60,3 Investment fees 43,514 - - 43,5 Seminars and summits 26,493 - - 54,7 Total expenditures 1,965,960 - - 1,965,9 Change in net assets before effect of new accounting pronouncement 946,046 632,525 - 1,578,5	Net realized and unrealized gains on						
Net assets released from restrictions 734,590 (734,590) - - Total revenue 2,912,006 632,525 - 3,544,5 Expenditures Grants 934,304 - - 934,3 Grants - EDRI 453,133 - - 453,1 Professional fees 393,484 - - 393,4 Travel and meetings 60,305 - - 60,3 Investment fees 43,514 - - 43,5 Seminars and summits 26,493 - - 26,4 General and administrative expenses 54,727 - - 54,7 Total expenditures 1,965,960 - - 1,965,9 Change in net assets before effect of new accounting pronouncement 946,046 632,525 - 1,578,5	investments		929,971		641,354	-	1,571,325
Total revenue 2,912,006 632,525 - 3,544,5 Expenditures Grants 934,304 - - 934,3 Grants - EDRI 453,133 - - 453,1 Professional fees 393,484 - - 393,4 Travel and meetings 60,305 - - 60,3 Investment fees 43,514 - - 43,5 Seminars and summits 26,493 - - 26,4 General and administrative expenses 54,727 - - 54,7 Total expenditures 1,965,960 - - 1,965,9 Change in net assets before effect 946,046 632,525 - 1,578,5	Other		1,664		-	-	1,664
Expenditures Grants 934,304 - - 934,3 Grants - EDRI 453,133 - - 453,1 Professional fees 393,484 - - 393,4 Travel and meetings 60,305 - - 60,3 Investment fees 43,514 - - 43,5 Seminars and summits 26,493 - - 26,4 General and administrative expenses 54,727 - - 54,7 Total expenditures 1,965,960 - - 1,965,9 Change in net assets before effect 946,046 632,525 - 1,578,5	Net assets released from restrictions		734,590		(734,590)	-	-
Grants 934,304 - - 934,3 Grants - EDRI 453,133 - - 453,1 Professional fees 393,484 - - 393,4 Travel and meetings 60,305 - - 60,3 Investment fees 43,514 - - 43,5 Seminars and summits 26,493 - - 26,4 General and administrative expenses 54,727 - - 54,7 Total expenditures 1,965,960 - - 1,965,9 Change in net assets before effect 946,046 632,525 - 1,578,5	Total revenue		2,912,006		632,525	-	3,544,531
Grants - EDRI 453,133 - - 453,1 Professional fees 393,484 - - 393,4 Travel and meetings 60,305 - - 60,3 Investment fees 43,514 - - 43,5 Seminars and summits 26,493 - - 26,4 General and administrative expenses 54,727 - - 54,7 Total expenditures 1,965,960 - - 1,965,9 Change in net assets before effect 946,046 632,525 - 1,578,5	Expenditures						
Professional fees 393,484 - - 393,484 Travel and meetings 60,305 - - 60,3 Investment fees 43,514 - - 43,5 Seminars and summits 26,493 - - 26,4 General and administrative expenses 54,727 - - 54,7 Total expenditures 1,965,960 - - 1,965,9 Change in net assets before effect 946,046 632,525 - 1,578,5	Grants		934,304		-	-	934,304
Travel and meetings 60,305 - - 60,3 Investment fees 43,514 - - 43,5 Seminars and summits 26,493 - - 26,4 General and administrative expenses 54,727 - - 54,7 Total expenditures 1,965,960 - - 1,965,9 Change in net assets before effect 946,046 632,525 - 1,578,5	Grants - EDRI		453,133		-	-	453,133
Investment fees 43,514 - - 43,5 Seminars and summits 26,493 - - 26,4 General and administrative expenses 54,727 - - 54,7 Total expenditures 1,965,960 - - 1,965,9 Change in net assets before effect 946,046 632,525 - 1,578,5	Professional fees		393,484		-	-	393,484
Seminars and summits 26,493 - - 26,4 General and administrative expenses 54,727 - - 54,7 Total expenditures 1,965,960 - - 1,965,9 Change in net assets before effect - 1,578,5 - 1,578,5	Travel and meetings		60,305		-	-	60,305
General and administrative expenses 54,727 54,7 Total expenditures 1,965,960 1,965,9 Change in net assets before effect of new accounting pronouncement 946,046 632,525 - 1,578,5	Investment fees		43,514		-	-	43,514
Total expenditures 1,965,960 1,965,9 Change in net assets before effect 946,046 632,525 - 1,578,5	Seminars and summits		26,493		-	-	26,493
Change in net assets before effect of new accounting pronouncement 946,046 632,525 - 1,578,5	General and administrative expenses		54,727		-	-	54,727
of new accounting pronouncement 946,046 632,525 - 1,578,5	Total expenditures		1,965,960			_	1,965,960
accounting propouncement	Change in net assets before effect						
accounting pronouncement - 1,286,333 (1,286,333) -	of new accounting pronouncement		946,046		632,525	-	1,578,571
	accounting pronouncement		-		1,286,333	(1,286,333)	-
CHANGE IN NET ASSETS 946,046 1,918,858 (1,286,333) 1,578,5	CHANGE IN NET ASSETS		946,046		1,918,858	 (1,286,333)	 1,578,571
	NET ASSETS, BEGINNING OF PERIOD		10,620,170				17,849,617
NET ASSETS, END OF PERIOD \$ 11,566,216 \$ 1,952,687 \$ 5,909,285 \$ 19,428,1	NET ASSETS, END OF PERIOD	\$	11,566,216	\$	1,952,687	\$ 5,909,285	\$ 19,428,188

 $See\ accompanying\ notes\ to\ financial\ statements.$

Statement of Activities

FOR THE YEAR ENDED DECEMBER 31, 2009

		nrestricted	emporarily estricted	P	ermanently Restricted	Total
Revenue						
Contributions and membership dues	\$	868,601	\$ 500,833	\$	-	\$ 1,369,434
Proceeds from fund raisers, net of direct						
benefit costs of \$194,696		233,029	-		-	233,029
Investment income		546,977	3,555		-	550,532
Net realized and unrealized gains on						
investments		642,467	3,982		439,937	1,086,386
Other		10,563			-	10,563
Net assets released from restrictions		733,335	(733,335)		-	-
Total revenue		3,034,972	(224,965)		439,937	 3,249,944
Expenditures			 			
Grants		1,046,157	-		-	1,046,157
Grants - EDRI		633,750	-		-	633,750
Professional fees		411,186	-		-	411,186
Travel and meetings		69,081	-		-	69,081
Investment fees		63,917	-		-	63,917
Seminars and summits		33,796	-		-	33,796
General and administrative expenses		64,123	-		-	64,123
Total expenditures		2,322,010	-		-	2,322,010
CHANGE IN NET ASSETS		712,962	(224,965)		439,937	927,934
NET ASSETS, BEGINNING OF PERIOD		9,907,208	258,794		6,755,681	16,921,683
NET ASSETS, END OF PERIOD	\$	10,620,170	\$ 33,829	\$	7,195,618	\$ 17,849,617

Statements of Cash Flows

For The Years Ended December 31, 2010 And 2009

	2010	2009
Cash flows from operating activities:		
Change in net assets	\$ 1,578,571	\$ 927,934
Adjustments to reconcile change in net assets to net		
cash provided by (used in) operating activities:		
Depreciation	370	535
Net realized and unrealized gains on investments	(1,571,325)	(1,086,386)
Changes in assets and liabilities:		
Contributions receivable	14,764	(18,629)
Other receivables	49,594	(21,819)
Prepaid expenses	(2,220)	9,384
Inventory	870	(126)
Accounts payable and accrued liabilities	(3,039)	(18,547)
Net cash provided by (used in) operating activities	 67,585	(207,654)
Cash flows from investing activities:		
Additions to fixed assets	(1,301)	-
Proceeds from sales of securities	10,422,361	18,896,814
Purchases of securities	 (10,434,652)	(19,034,108)
Net cash used in investing activities	 (13,592)	(137,294)
Net change in cash and cash equivalents	53,993	(344,948)
Cash and cash equivalents, beginning of period	 575,106	920,054
Cash and cash equivalents, end of period	\$ 629,099	\$ 575,106
	 _	

NOTE 1 – ORGANIZATION

On August 3, 1989, Grayson Foundation merged with the Jockey Club Research Foundation to create the Grayson-Jockey Club Research Foundation, Inc. (the "Foundation"). The purpose of this organization is to further research and education in the equine industry. The Foundation is exempt from Federal income taxes under Section 501(c)(3) of the Internal Revenue Code and is also exempt from state and local income taxes.

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES

Net assets

The accounts of the Foundation are maintained on the basis of unrestricted, temporarily restricted and permanently restricted net assets. Unrestricted net assets are available to support research programs approved by the Board of Directors (the "Board") and to fund general operations. Temporarily restricted net assets relate to donations that have been either pledged but not yet received and/or subject to donor restrictions as well as related gains and losses of the endowment fund. Permanently restricted net assets are subject to donor restrictions and require that the principal remain invested in perpetuity and the income earned therefrom be available in temporarily restricted net assets to fund research programs and general operations.

Use of estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents

Cash and cash equivalents consist of short term, highly liquid investments which are readily convertible into cash and have original maturities of three months or less when purchased. The Foundation maintains amounts on deposit with various financial institutions, which may, at times, exceed Federally insured limits. However, the Foundation periodically evaluates the creditworthiness of those institutions and the Foundation has not experienced any losses on such deposits.

Investments

Investments are reported at fair value. The fair value of such investments is based on quoted market prices.

Fixed assets

Fixed assets are comprised of office and computer equipment. Depreciation is calculated using the straight-line method over the estimated useful life of the assets ranging from three to five years.

Revenue recognition

Contributions are recorded when an unconditional promise to give is made by the donor. As of December 31, 2010 and 2009, contributions receivable as reported on the Statements of Financial Position are all due within one year.

Grants

Grants are recorded in the period the funds are disbursed.

Professional services

The management and staff of the Foundation are employees of The Jockey Club and their related salaries and fringe benefits are billed to the Foundation pursuant to agreements between the parties. These costs totaled \$341,924 and \$360,868 in 2010 and 2009, respectively, and are included in Professional fees in the accompanying Statements of Activities. Additionally, certain administrative services (e.g., accounting and certain office space) are provided by The Jockey Club. These services are not reflected in the accompanying Financial Statements since such amounts would not be material.

Income taxes

Accounting principles generally accepted in the United State of America prescribes recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Tax benefits will be recognized only if the tax position is more likely than not sustained in a tax examination, with a tax examination being assumed to occur. The amount recognized will be the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the more likely

than not test, no tax benefit will be recorded. For the years ended December 31, 2010 and 2009, no income tax liability has been recognized related to uncertain tax provisions in the accompanying Financial Statements.

If an uncertain tax position was recognized, the Foundation would accrue interest and penalties associated with the uncertain tax position. For the Foundation's major tax jurisdictions, the 2007, 2008, and 2009 tax years remain subject to examination. The Foundation does not expect significant changes in unrecognized tax benefits in the next twelve months.

Accounting pronouncements

The Foundation adopted the provisions of Financial Accounting Standard Board ASC 958-205 which provides guidance on the net asset classification of donor restricted endowment funds for organizations subject to an enacted version of the Uniform Prudent Management of Institutional Funds Act ("UPMIFA"). Upon adoption, \$1,286,333 of permanently restricted net assets was transferred to temporarily restricted net assets in accordance with the law enacted by the State of New York. Additional disclosure is provided in Note 5.

Other than noted above, the adoption of other recently effective accounting standards did not have a material effect on the Foundation's Financial Statements nor does the Foundation believe that any other recently issued, but not yet effective, accounting standards will have a material effect on the Foundation's Statement of Financial Position or Statement of Activities.

NOTE 3 – INVESTMENTS

Investments at fair value consist of the following:

	2010	2009
Mutual funds	\$ 9,627,799	\$ 5,483,620
US equities	2,948,710	3,939,628
Fixed income - treasury	3,068,675	4,120,222
Fixed income - corporate	2,523,758	3,627,725
Fixed income - agency	585,869	-
	\$18,754,811	\$17,171,195

Interest and dividend earnings on these investments were \$331,235 and \$549,483 in 2010 and 2009, respectively. Net realized and unrealized gains from investments reported in the accompanying Statements of Activities totaled \$1,571,325 and \$1,086,386 in 2010 and 2009, respectively.

NOTE 4 – FAIR VALUE MEASUREMENTS

ASC 820-10 establishes a hierarchal disclosure framework which prioritizes and ranks the level of market price observability used in measuring investments at fair value. Market price observability is impacted by a number of factors, including the type of investment and the characteristics specific to the investments. Investments with readily available active quoted prices or for which fair value can be measured from actively quoted prices generally will have a higher degree of market observability and a lesser degree of judgment used in measuring fair value.

Investments measured and reported at fair value are classified and disclosed in one of the following categories:

Level I – Quoted prices are available in active markets for identical investments as of the reporting date. The type of investments included in Level I are publicly traded securities.

Level II – Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies.

Level III – Pricing inputs are unobservable and include situations where there is little, if any, market activity for the investment. Fair value for these investments is determined using valuation methodologies that consider a range of factors, including but not limited to the price at which the investment was acquired, the nature of the investment, local market conditions, trading values on public exchanges for comparable securities, current and projected operating performance and financing transactions subsequent to the acquisition of the investment. The inputs into the determination of fair value require significant judgment.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an investment's level within the fair value hierarchy is based on the lowest level that is significant to the fair value measurement. Management's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the investment.

The following table summarizes the valuation of the Foundation's investments by the ASC 820-10 fair value hierarchy as of December 31, 2010:

		Total	Level I		Level II	Level III
Mutual funds:	_				 	
US equities	\$	7,682,669	\$	7,682,669	\$ -	\$ -
International equities		1,945,129		1,945,129	_	-
Fixed income:						
Corporate		2,523,758		2,523,758	-	-
Treasury		3,068,675		3,068,675	_	-
Agency		585,869		585,869	-	-
US equities:						
Energy		646,194		646,194	_	-
Financial		477,052		477,052	_	-
Health care		417,730		417,730	-	-
Industrials		415,493		415,493	_	-
Information technology		368,066		368,066	_	-
Consumer staples		346,965		346,965	-	-
Consumer discretionary		154,470		154,470	_	-
Materials		122,741		122,741	-	-
	\$	18,754,811	\$	18,754,811	\$ 	\$

The following table summarizes the valuation of the Foundation's investments by the ASC 820-10 fair value hierarchy as of December 31, 2009:

	Total	Level I	Level II	I	Level III
Investments	\$ 17,171,195	\$ 17,171,195	\$ -	\$	_

The 2010 fair value hierarchy table includes expanded investment disclosures as required by ASC 320-10-50, which was effective January 1, 2010.

NOTE 5 - ENDOWMENTS

The Foundation's permanently restricted net assets consist of investments to be held indefinitely, the income from which is expendable to support the purpose of the Foundation and its operations. The Foundation's endowment fund consists of donor-restricted endowment funds and the related gains and losses that accumulate on the donor-restricted endowment funds. As required by applicable standards, net assets associated with endowment funds, including funds designated by the Board to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

Endowment net assets composition by type of fund as of December 31, 2010:

	Temporarily	Permanently	
	Restricted	Restricted	<u>Total</u>
Donor-restricted endowment funds	\$ 1,927,687	\$ 5,909,285	\$ 7,836,972

Changes in endowment net assets for the year ended December 31, 2010:

	-	Femporarily]	Permanently	
		Restricted	_	Restricted	Total
Net assets, beginning of year	\$	-	\$	7,195,618	\$ 7,195,618
Investment return:					
Investment income, net		135,197		-	135,197
Net realized and unrealized					
gains of investments		641,354		-	641,354
Total investment return		776,551		=	776,551
Net asset reclassification based on accounting change		1,286,333		(1,286,333)	-
Appropriation of assets for expenditure		(135,197)		-	(135,197)
Net assets, end of year	\$_	1,927,687	\$_	5,909,285	\$ 7,836,972

<u>Interpretation of UPMIFA</u>

On September 17, 2010, the State of New York's version of the UPMIFA became effective for all non-profit, charitable organizations including the Foundation. The Foundation has interpreted UPMIFA as requiring the preservation of the fair value of the original and subsequent gifts as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary.

As a result of this interpretation, the Foundation classifies as permanently restricted net assets

- (a) the original value of the principal designated as an endowment,
- (b) the original value of the principal of subsequent gifts to the endowment, and
- (c) the accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund.

The remaining portion of the donor-restricted endowment fund that is not classified in permanently restricted net assets is classified as temporarily restricted net assets until those amounts are appropriated for expenditure by the Foundation in a manner consistent with the standard prudence prescribed by UPMIFA. In accordance with UPMIFA, the Foundation considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

- 1. The duration and preservation of the fund
- 2. The purposes of the organization and the donor-restricted endowment fund
- 3. General economic conditions
- 4. The possible effect of inflation and deflation
- 5. The expected total return from income and the appreciation of investments
- 6. Other resources of the Foundation
- 7. The investment policies of the Foundation

Return Objectives and Risk Parameters

The Foundation has adopted investment and spending policies for endowment assets that attempt to provide predictable streams of funding to programs supported by its endowment while seeking to maintain the purchasing power of the endowment assets. Endowment assets include those assets of donor-restricted funds that the Foundation must hold in perpetuity or for a donor-specified period as well as Board-designated funds. Under this policy, as approved by the Board, the Foundation relies on a total return strategy in which investment returns are achieved through capital appreciation (realized and unrealized) and current yield (interest and dividends). The Foundation targets a diversified asset allocation that places a greater emphasis on equity-based investments to achieve its long-term return objectives within prudent risk constraints.

Strategies Employed for Achieving Objectives

The purpose of the endowment fund is to facilitate donors' desires to make substantial long-term gifts to the Foundation to develop a new and significant source of revenue of the Foundation. In so doing, the endowment fund will provide a secure, long-term source of funds to (a) carry out the Foundation's purpose of furthering research and education in the equine industry or, (b) support the operational expenses of the Foundation as deemed appropriate.

Spending Policy and How the Investment Objectives Relate to the Spending Policy

The distribution rate is based upon withdrawing the investment income for spending each year and allowing capital appreciation to be reinvested in the fund. For the year ended December 31, 2010, \$135,197 of investment income from the endowment fund was spent and none of the capital appreciation was spent. The spending is determined by the Foundation's management, who may elect to make no distributions from the fund in any given year.

Funds with Deficiencies

From time to time, the fair value of assets associated with donor-restricted endowment funds may fall below the level that the donor or UPMIFA requires the Foundation to retain as a fund of perpetual donation. Deficiencies of this nature that are in excess of related temporarily restricted amounts are reported in unrestricted net assets. There were no such delinquencies as of December 31, 2010 and 2009.

NOTE 6 – FUNCTIONAL CLASSIFICATION OF EXPENSES

For the years ended December 31, 2010 and 2009, the Foundation incurred \$1,965,960 and \$2,322,010 in expenses, respectively, as reported in the accompanying Statements of Activities. Those expenses by their functional classifications are as follows:

	 2010								
	Program		Fundraising		/Ianagement	t			
	 Services		Services		& General		Total		
Grants	\$ 934,304	\$	-	\$	-	\$	934,304		
Grants - EDRI	453,133		-		-		453,133		
Professional fees	97,363		225,913		70,208		393,484		
Travel and meetings	48,160		9,716		2,429		60,305		
Investment fees	_		-		43,514		43,514		
Printing	1,135		9,986		227		11,348		
Seminars and summits	26,493		_		-		26,493		
Members reception	-		11,104		-		11,104		
Fundraising events	-		158		-		158		
Other	 548		6,351		25,218		32,117		
	\$ 1,561,136	\$	263,228	\$	141,596	\$	1,965,960		

	2009							
	Program Services		Fundraising Services		Management & General		Total	
Grants	\$	1,046,157	\$	_	\$	-	\$	1,046,157
Grants - EDRI		633,750		_		-		633,750
Professional fees		85,955		250,524		74,707		411,186
Travel and meetings		51,681		15,764		1,636		69,081
Investment fees		-		-		63,917		63,917
Printing		1,331		11,703		267		13,301
Seminars and summits		33,796		-		-		33,796
Members reception		-		11,377		-		11,377
Fundraising events		-		3,361		-		3,361
Other		1,022		10,920		24,142		36,084
	\$	1,853,692	\$	303,649	\$	164,669	\$	2,322,010

NOTE 7 – SUBSEQUENT EVENTS

The Foundation has evaluated subsequent events through the date the accompanying Financial Statements were available to be issued, which was June 2, 2011. No subsequent events have been identified that are required to be accounted for or disclosed.

ROKEBY CIRCLE

In honor of the generosity to the Foundation by the late Paul Mellon, Grayson-Jockey Club designates inclusion in the Rokeby Circle for those donors at the \$10,000-plus level within the year. The honor is named for Rokeby Farm, Mr. Mellon's estate in Virginia.

Prince Khalid Abdullah

Joseph Allen

Austin Lang Testamentary Trust

William M. Backer,

William M. Backer Foundation

Ramona & Lee Bass

Mr. & Mrs. John T. Behrendt

Anthony Bonomo

Breeders' Cup Ltd.

Alexander G. Campbell Jr.

Mr. & Mrs. W. Cothran Campbell,

Dogwood Stables

Sherwood Chillingworth

Claiborne Farm

Mr. & Mrs. Dennis Dammerman

Darley America

Adele B. Dilschneider

Donald R. & Irene Dizney

Lee R. Einsidler,

LRE Racing LLC

William S. Farish

William S. Farish Jr.

William Stamps Farish Fund

Fasig Tipton Company

Mr. & Mrs. Bertram R. Firestone

Dr. Susan Galandiuk

Gary Broad Foundation

John K. Goodman

James Gordon Grayson Trust

Laura Grayson Trust

David Greathouse

John Greathouse III

Lucy Young Hamilton

Clay Hancock

Dell Hancock

Seth W. Hancock

Ian Highet

HRTV

The Jockey Club

Johnson & Johnson Consumer

Products Company

Kentucky Thoroughbred

Association, Inc.

Ronald Kirk, Kirk Horse Insurance

Dr. & Mrs. A. Gary Lavin

Robert Lewis & Beverly Lewis

Family Foundation

Robert E. Meyerhoff

Mrs. J. M. Moran

NTRA Charities

New York Racing Association

New York Yankees Foundation

North American Specialty

Insurance Company/ Swiss Group

Oak Tree Racing Association

Mr. & Mrs. John M. B. O'Connor

Paul F. Oreffice

John C. Oxley

The Oxley Foundation

Ogden Mills Phipps

Dr. Hiram C. Polk

Carl Pollard

Louise & Leonard Riggio

Rood & Riddle Equine Hospital

Richard Santulli

Mr. & Mrs. Barry Schwartz

Mr. & Mrs. Joseph V. Shields

Mace Siegel

Stella Thayer, Tampa Bay Downs

Thoroughbred Charities of

America

Thoroughbred Owners & Breeders

Association

James R. Treptow

Virginia G. Valentine

Jack Weakley

Charlotte C. Weber

PLATINUM CIRCLE

Elizabeth Locke Jewels Helen K. Groves Mr. & Mrs. Stuart Subotnick

GOLD CIRCLE

Josephine Abercrombie

American Association of Equine

Practitioners

Mr. & Mrs. Chester Broman

Charles J. Cella

Del Mar Thoroughbred Club

Richard L. Duchossois

Mr. & Mrs. C. S. Duncker

Mr. & Mrs. William Entenmann

Robert S. Evans Joseph W. Harper

The Hon. & Mrs. Brereton

& Elizabeth Jones

Kevin Lavin

Jacqueline B. Mars

Mr. & Mrs. Leverett S. Miller

Milliman

Dr. Wilfrid R. Robinson

William T. Young

SILVER CIRCLE

Irving Cowan

Tom Durkin

Mr. & Mrs. Joe T. Ford

Arthur Hancock III

Michael Hess

Dr. Patricia M. Hogan

Hollywood Park Racing

Association

Dr. James Hunt Jr.

Hon. & Mrs. Earle I. Mack

John McCormack

Mohegan Sun

Ann & Jerry Moss

NTRA

Oaklawn Jockey Club

Andrew Rosen

Secretariat Foundation Inc. Mr. & Mrs. Michael Simpson

Mary Sullivan

The Dobson Foundation

UHY, LLP

Warren Williamson

PATRON

Adena Springs

John H. Adger

Mr. & Mrs. John & Jerry Amerman

Dr. Rick M. Arthur

Madeline Auerbach

John Barr

Frank A. Bonsal

James C. Brady

Brian J. Ratner Philanthropic Fund

John J. Brunetti

Charlsie Cantey

Anita Cauley

Alice Chandler

Case Clay

Marty Cunningham

Duke of Devonshire

Shawna Dietrich

Monica Driver

Sandy Dubose

Equine Medical Associates, PSC

P. F. N. Fanning

Hugh A. Fitzsimons

Charles Hayward

Mr. & Mrs. Steven Holland

Jody & Michelle Huckabay

Stuart S. Janney

Mr. & Mrs. Jon S. Kelly

Kentucky Thoroughbred Farm

Managers Club

Klein Family Foundation

F. Jack Liebau

r. Jack Liebau

Robin Lightner

Bruce Lunsford

Robert T. Manfuso

J. W. Y. Martin

Kiaran & Letty McLaughlin

Janice and Robert C. McNair

Mill Ridge Farm Ltd.

John Nigro

Hayward R. Pressman, Esq.

Peter G. Schiff

Mr. & Mrs. A. J. C. Smith

Diane Snowden

Team Valor International LLC

Teigland, Franklin & Brokken

DVMs, P.A.

Oakleigh B. Thorne

Robert Trussell

John Velazquez

John Velazquez

Peter S. Willmott

Arnold B. Zetcher

SUPPORTING

Thomas Albertrani John Ed Anthony Laura Barillaro

Mr. & Mrs. Michael Baum

Reynolds Bell Jr. The Bell Group Gary Biszantz Edward L. Bowen

Mr. & Mrs. Darrell Brown

Thomas R. Capehart Robert E. Courtney

Darley Stud Management LLC

Isabelle H. de Tomaso

Michael Dubb Linda C. Elliott

Equine Veterinary Care, PC

Robert Fabbricatore W. D. Fishback

Mr. & Mrs. Frank Gardner

C. Kenneth Grayson
Carl Hamilton
John C. Harris
George I. Harris
Vanessa S. Jenkin
Hope H. Jones

Annie Jones Richard W. Kelso Michael R. Matz

Claude R. McGaughey Richard W. Meister Todd Muchnicki

J. Michael O'Farrell

Louis Ottrando

Mr. & Mrs. Todd Pletcher

Lee Pokoik
Kate Quigley
R. Alex Rankin
Patricia C. Reavy

J. Kirk & Judy Robison

Hal Snowden

Beverly R. Steinman Frederic Stutzman Edward Swyer James B. Tafel

William B. Thompson
West Point Thoroughbreds

Peter Zacchea

SUSTAINING

Jay Addison

C. W. and Kathryn Asmus Peter & Debbie Backus

Beverly Bower

Frank & Donna Brothers

Tom Bush

Byars Equine Advisory LLC Mr. & Mrs. Bruzzy Cooke

Kyle W. Cooper Paul Corliss

Robert Cornacchia

D. Sutherland Horse Transport

Fay & David Donk James M. Durlacher

Daryl Easley

Dr. Claire Latimer Embertson

Dr. Rolf Embertson
Dr. Edward H. Fallon
Matthew Gatsas
Richard L. Hamilton

Charles and Susan Harris

W.T. Hill

Mrs. C. O. Iselin

Japan Racing Association

Dr. David T. Lamb
William M. Lear
James S. Liao
Braxton J. Lynch
Charles E. Mather
Dr. Wayne McIlwraith

McMahon Bloodstock LLC

Judy P. Miller

Morgan's Ford Farm LLC

Patricia Moseley

Graham & Anita Motion

Niall Brennan Stables Joe Browne Nicholson

Richard Nieminski

New York Thoroughbred Breeders

Bud Paul

William G. Reck

J. D. Richardson

Walt Robertson

Mrs. Leonard P. Sasso Mr. & Mrs. Edgar Scott

Joann L. Scudder Michael Shanley Jonathan Sheppard

Michael K. Tivnan

United/Puett Electrical Starting Gate

Harold Via

Richard S. Walden

Sally Warner

John A. Waterman

Margaret A. Weygand

Ian Wilkes

Brian and Arlene Wilkins

Beverly Yunich

Henry A. Zeitlin

ANNUAL

Mr. & Mrs. Anthony M. Alonso

Rusty Arnold

Mr. & Mrs. Joseph Aulisi

Helen Ayer

Randall C. Bassett

Bathen Thoroughbreds LLC

Katrina H. Becker

Bill Belton Patricia Birk

The Blood-Horse Charitable

Foundation Lola E. Bonner

Fred and Buff Bradley

Adam Brehm Brookdale Farm Magalen Bryant Thomas Caminiti Gilbert G. Campbell

Mr. & Mrs. Peter J. Canzone Sr.

Sean Clancy Catesby W. Clay

Nancy Cole, Corner Woods

Joshua Cooper Leonard F. Donahoo

William duPont

Edward Plesa Racing Stable, Inc

Mr. & Mrs. H. J. Elkins Christopher L. Elser Mrs. Henry N. Eyre Richard M. Feldman

Martin Fox Dr. Ben Franklin James E. Friess

Mitch and Angela Frisby

James Glasser Alan Goldberg Lucy Goodman Curtis C. Green

Robert Hachemeister

Louis L. Haggin Dr. Laine W. Hills Neil A. Howard

Suzette A. Howard

Illinois TBOF Barbara S. Jackson

Tim Jackson

Mrs. Bettina L. Jenney Dr. Ronald C. Jensen

Kyle Kehner
Patrick Kehoe
Susan Keiser
Joe King
Scott A. Kivi
William Landes
Bruce Levine

Mr. & Mrs. Leon Lieberman Mr. & Mrs. Albert L. Luedtke

D. Paul Lunn Preston Madden Ronald McAnally

Mr. & Mrs. R. Shannon McDonald

Mrs. G. W. Merck
Frances Merryman
Mrs. Dudley L. Millikin
Elizabeth S. Millikin
Kerry T. Millikin
Michael Mitchell

Nassau Downs Off-Track

Betting Corp Charles Nuckols III James O'Grady Deborah O'Kain Ginny F. Orthwein

Dave Parnell

Mr. & Mrs. William Patterson

John W. Phillips Catherine L. Powell

Pro Bose

Donald N. Reeves Barbara Rehbein Maggie Rikard John A. Schaffer Christopher Scherf

Julie Scofield

Frederick C. Shiery
Dr. Johnny Mac Smith
Dr. Daniel C. Stearns
James E. Stoller
Michael Taylor

Mr. & Mrs. Peter Tenbeau

Jill A. Thacher
Peggy A. Theobald
Joanna L. Trout
Steve Turcotte
Robert M. Vance
Lynn Veitch
Cheryl A. Weeks
Max Weintraub
Lauren Welch
Kristin M. Werner

Sandra Whitley
Wheelock Whitney
Joseph Wilson

Mr. & Mrs. L. Wisniewski

Patrice Wolfson William W. Wright

ADDITIONAL CONTRIBUTIONS

Josephine E. Abercrombie

Mary J. Aboud
Beth Alexander
Anonymous
Amanda Barnes
Carolyn Barnes
Katrina H. Becker

The Blood-Horse Charitable

Foundation

Sue Blessing

The Blood-Horse Magazine

Blue Grass Tours

Bridgforth Farms LLC

Mr. & Mrs. W. Cothran Campbell

Claiborne Farm

Cora & Lillian Cushny Sandra K. Danner Jonathan K. Davis Jim Doolan

Estelle & John S. Doyle Christopher Dubeck

Carl Ellis
Vickie Forster

Rochelle Gandour

Mafalda Garges Louis L. Haggin

Lucy Y. Hamilton

Clay Hancock

Michael W. Hanna Nancy Hapgood Jodi Hartlep

Leah & Greg Hayes
Doris Ann Hayes
Doris Henton
Howard M. Hickey
Timothy A. Hills

Holly Hill Training Center, LLC

The Jockey Club Anne Johnson Diane G. Johnston Barbara Kamber Mary Keiser Elizabeth A. Koch

Lane's End Brenda Lee

Deborah Logerquist Michelle MacDonald Martha Buster Martin Stewart D. Maurice

Amy Merkel Patricia Moseley

National Museum of Racing

Lori Neises No Mas

Billie Sue Nutter

NYRA

Suzanne Peugeot

Dr. & Mrs. Winston Pirtle

Kay Pitts

Marilyn A. Quinn Deborah J. Quirk Valorie B. Rivero James Rouse D. Shegog Alexis Theriault Leslie Thomas

Harry & Kathryn Thompson

The Thorobreds Ralph J. Tramantano

Sally Warner

Charlotte C. Weber Kathryn Webers Wheelock Whitney Mrs. Bennett B. Williams

Eric J. Wirth

Event Support

Adena Springs Thomas Albertrani

Mr. & Mrs. Anthony M. Alonso Mr. & Mrs. Joseph Aulisi

John Barr

Ramona & Lee Bass

Erica Basso

Bee Ready Fishbein Hatter & Donovan

Reynolds Bell Jr. Bessemer Trust

Bollam, Sheedy & Torani Mr. & Mrs. Anthony Bonomo

James C. Brady Molly Brindle

Mr. & Mrs. Chester Broman

Brushwood Stable Tom Bush Stables Charles J. Cella

Certilman Balin Adler & Hyman LLP

Claiborne Farm

Mr. & Mrs. Robert Cornacchia

Marty Cunningham

Bob Curran

D. Sutherland Horse Transport

Daily Racing Form Darley America Adele B. Dilschneider

David Dizney

Donald R. & Irene Dizney Leonard F. Donahoo Fay & David Donk Michael Dubb

Mr. & Mrs. C. S. Duncker

Tom Durkin John Ehrhardt

Lee R. Einsidler, LRE Racing, LLC

Equibase Company Flaxman Holdings Martin & Susan Fox Jim Gallagher

Alan Goldberg Jason Golden Helen K. Groves Robert Hachemeister

Matthew Gatsas

Ross Haime Dell Hancock

Charles and Susan Harris

Charles Hayward Michael Hess Ian Highet

Dr. Patricia M. Hogan

Hollywood Park Racing Association

Dr. James Hunt, Jr. & Associates P.C.

Japan Racing Association

The Jockey Club

The Jockey Club Information

Systems, Inc. Nancy C. Kelly Lane's End Juliane Levine

Hon. & Mrs. Earle I. Mack

Robert T. Manfuso, Chanceland Farm

Kiaran & Letty McLaughlin

Richard W. Meister

Milliman

Graham & Anita Motion, Herringswell Stables, Ltd.

Todd Muchnicki Steve Napolitano Rita Nash

Nassau Downs Off-Track

Betting Corp NTRA

New York Racing Association New York Thoroughbred Breeders

New York Thoroughbred Horsemen's Association Leona & Richard Nieminski

John Nigro

O'Sullivan & Zacchea PLLC Oak Tree Racing Association Mr. & Mrs. John M. B. O'Connor

Paul & Jo Ann Oreffice

Mr. & Mrs. Todd Pletcher Lee & Kathie Pokoik Dr. Hiram C. Polk Jr.

Hayward R. Pressman, Esq.

Kate Quigley William G. Reck

Louise & Leonard Riggio

Rood & Riddle Equine Hospital

Diane Salek

Richard & Peggy Santulli, Colts Neck Stables Mr. & Mrs. Peter G. Schiff

Joann L. Scudder Mike Sellitto

Mr. & Mrs. Michael Shanley Mr. & Mrs. Jonathan Sheppard

Mace Siegel Vince Smith

Beverly R. Steinman

Frederic Stutzman, Hudson River

Construction Co., Inc. Mr. & Mrs. Stuart Subotnick

Mary Sullivan Edward Swyer J. Thomas

Triple Crown Horse Feed

UHY, LLP

United/Puett Electrical Starting Gate

Lynn Veitch John Velazquez Jennifer Weigand Marylou Whitney & John Hendrickson Joseph Wilson

June T. Wilson Beverly Yunich

Members

Donors whose contributions or portions thereof are designated as dues for membership shall have the privilege of participating in the annual election of the board of directors.

Prince Khalid Abdullah Josephine Abercrombie

Jay Addison John H. Adger Thomas Albertrani Joseph Allen

American Association of Equine

Practitioners

Mr. & Mrs. John & Jerry Amerman

John Ed Anthony
Rusty Arnold
Dr. Rick M. Arthur
C. W. & Kathryn Asmus
Madeline Auerbach

Austin Lang Testamentary Trust

Helen Ayer

William M. Backer

Mr. & Mrs. Peter & Debbie Backus

John Barr

Ramona & Lee Bass Randall C. Bassett

Bathen Thoroughbreds LLC Mr. & Mrs. Michael Baum

Katrina H. Becker

Mr. & Mrs. John T. Behrendt

The Bell Group Bill Belton Patricia Birk Gary Biszantz

The Blood-Horse Charitable

Foundation
Lola E. Bonner
Anthony Bonomo
Frank A. Bonsal
Edward L. Bowen
Beverly Bower
Fred and Buff Bradley

Pred and Buff Bradley Dr. Larry R. Bramlage Breeders' Cup Ltd.

Adam Brehm

Brian J. Ratner Philanthropic Fund

Mr. & Mrs. Chester Broman

Brookdale Farm

Frank & Donna Brothers Mr. & Mrs. Darrell Brown

John J. Brunetti Magalen Bryant

Byars Equine Advisory LLC

Thomas Caminiti

Alexander G. Campbell Jr.

Mr. & Mrs. W. Cothran Campbell,

Dogwood Stables Gilbert G. Campbell Charlsie Cantey

Mr. & Mrs. Peter J. Canzone Sr.

Thomas R. Capehart

Anita Cauley Charles J. Cella Alice Chandler

Sherwood Chillingworth

Claiborne Farm Sean Clancy Case Clay Catesby W. Clay

Nancy Cole, Corner Woods Mr. & Mrs. Bruzzy Cooke

Joshua Cooper Kyle W. Cooper Paul Corliss Robert E. Courtney

Irving Cowan

Mr. & Mrs. Dennis Dammerman

Darley America

Darley Stud Management LLC

Isabelle H. de Tomaso Del Mar Thoroughbred Club

Duke of Devonshire Shawna Dietrich Adele B. Dilschneider Donald R. & Irene Dizney

Monica Driver Michael Dubb Sandy Dubose

Richard L. Duchossois

Mr. & Mrs. C. S. Duncker

William duPont James M. Durlacher

Daryl Easley

Edward Plesa Racing Stable, Inc

Lee R. Einsidler, LRE Racing LLC Elizabeth Locke Jewels Mr. & Mrs. H. J. Elkins

Linda C. Elliott Christopher L. Elser

Dr. Claire Latimer Embertson

Dr. Rolf Embertson

Mr. & Mrs. William Entenmann Equine Medical Associates, PSC Equine Veterinary Care, PC

Robert S. Evans Mrs. Henry N. Eyre Robert Fabbricatore Dr. Edward H. Fallon P. F. N. Fanning William S. Farish William S. Farish Jr.

William Stamps Farish Fund Fasig Tipton Company Richard M. Feldman

Mr. & Mrs. Bertram R. Firestone

W. D. Fishback Hugh A. Fitzsimons Mr. & Mrs. Joe T. Ford Dr. Ben Franklin James E. Friess

Mitch and Angela Frisby Dr. Susan Galandiuk Mr. & Mrs. Frank Gardner Gary Broad Foundation

James Glasser Lucy Goodman John K. Goodman C. Kenneth Grayson

James Gordon Grayson Trust

Laura Grayson Trust

Members

David Greathouse John Greathouse III Curtis C. Green Helen K. Groves Louis L. Haggin Carl Hamilton Lucy Y. Hamilton Richard L. Hamilton Arthur Hancock III Clay Hancock Dell Hancock Seth W. Hancock Joseph W. Harper George I. Harris John C. Harris Charles Hayward

Dr. William T. Hill Dr. Laine W. Hills

Ian Highet

Mr. & Mrs. Steven Holland

Neil A. Howard Suzette A. Howard

HRTV

Jody & Michelle Huckabay

Illinois TBOF
Mrs. C. O. Iselin
Barbara S. Jackson
Timothy A. Jackson
Stuart S. Janney
Vanessa S. Jenkin
Bettina L. Jenney
Dr. Ronald C. Jensen
Johnson & Johnson Const.

Johnson & Johnson Consumer

Products Company

Annie Jones Hope H. Jones

The Hon. & Mrs. Brereton &

Elizabeth Jones Kyle Kehner Patrick Kehoe Susan Keiser

Mr. & Mrs. Jon S. Kelly Richard W. Kelso

Kentucky Thoroughbred Association, Inc.

Kentucky Thoroughbred Farm

Managers Club

Joe King

Ronald Kirk, Kirk Horse Insurance

Scott A. Kivi

Klein Family Foundation

Dr. David T. Lamb William Landes

Dr. & Mrs. A. Gary Lavin

Kevin Lavin William M. Lear Bruce Levine

Robert Lewis & Beverly Lewis

Family Foundation

James S. Liao F. Jack Liebau

Mr. & Mrs. Leon Lieberman Robin Lightner, Lightner Sams Foundation of Wyoming, Inc.

Mr. & Mrs. Albert L. Luedtke

D. Paul Lunn Bruce Lunsford Braxton J. Lynch

Hon. & Mrs. Earle I. Mack

Preston Madden Robert T. Manfuso Jacqueline B. Mars J. W. Y. Martin Charles E. Mather

Mr. & Mrs. Michael R. Matz

Ronald McAnally John McCormack

Mr. & Mrs. R. Shannon McDonald

Claude R. McGaughey
Dr. Wayne McIlwraith
Letty & Kiaran McLaughlin
McMahon Bloodstock LLC
Janice and Robert C. McNair

Mrs. G. W. Merck Frances Merryman Robert E. Meyerhoff Mill Ridge Farm Ltd.

Judy P. Miller Leverett S. Miller Mrs. Dudley L. Millikin Elizabeth S. Millikin Kerry T. Millikin

Michael Mitchell Racing Stable

Mohegan Sun Mrs. J. M. Moran

Morgan's Ford Farm LLC

Patricia Moseley Ann & Jerry Moss

NTRA

NTRA Charities

New York Racing Association New York Yankees Foundation

Niall Brennan Stables Joe Browne Nicholson North American Specialty

Insurance Company/ Swiss Group

Charles Nuckols III

Oak Tree Racing Association

Oaklawn Jockey Club

Mr. & Mrs. John M. B. O'Connor

J. Michael O'Farrell James O'Grady Deborah O'Kain Paul F. Oreffice Ginny F. Orthwein Louis Ottrando

John C. Oxley
The Oxley Foundation

Dave Parnell

Mr. & Mrs. William Patterson

Bud Paul II John W. Phillips Ogden Mills Phipps Dr. Hiram C. Polk Carl Pollard

Catherine L. Powell

Pro Bose

Daisy Phipps Pulito R. Alex Rankin Patricia C. Reavy William G. Reck Donald N. Reeves Barbara Rehbein J. D. Richardson

Louise & Leonard Riggio

Members

Maggie Rikard Dr. Jack V. Robbins Walt Robertson

Dr. Wilfrid R. Robinson J. Kirk & Judy Robison

Rood & Riddle Equine Hospital

Andrew Rosen Geoffrey Russell Richard Santulli

Mrs. Leonard P. Sasso John A. Schaffer

Christopher Scherf Peter G. Schiff

Mr. & Mrs. Barry Schwartz

Julie Scofield

Mr. & Mrs. Edgar Scott Secretariat Foundation Inc. Mr. & Mrs. Joseph V. Shields

Frederick C. Shiery

Mace Siegel

Mr. & Mrs. Michael Simpson Mr. & Mrs. A. J. C. Smith Dr. Johnny Mac Smith

Diane Snowden Hal Snowden

Dr. Daniel C. Stearns Mrs. Beverly R. Steinman James E. Stoller

Mr. & Mrs. Stuart Subotnick

James B. Tafel Tampa Bay Downs Michael Taylor

Team Valor International LLC Teigland, Franklin & Brokken

DVMs, P.A.

Mr. & Mrs. Peter Tenbeau

Jill A. Thacher Stella Thayer Peggy A. Theobald William B. Thompson Oakleigh B. Thorne

Thoroughbred Charities of America Thoroughbred Owners & Breeders

Association Michael K. Tivnan James R. Treptow Joanna L. Trout Robert Trussell Steve Turcotte

Virginia G. Valentine Robert M. Vance John Velazquez Harold Via Richard S. Walden

Sally Warner John A. Waterman Jack Weakley Charlotte C. Weber Cheryl A. Weeks Max Weintraub Lauren Welch Kristin M. Werner

West Point Thoroughbreds Margaret A. Weygand Sandra Whitley Wheelock Whitney

Ian Wilkes

Brian & Arlene Wilkins Warren Williamson Peter S. Willmott

Mr. & Mrs. L. Wisniewski

Patrice Wolfson William W. Wright

William T. Young, Overbrook Farm

Henry A. Zeitlin Arnold B. Zetcher

At the end of 2010, membership stood at 324, compared to 327 at the end of 2009. Names and addresses of members are maintained in the Foundation's offices at 821 Corporate Drive Lexington, Kentucky 40513.

TAX STATUS OF GRAYSON-JOCKEY CLUB RESEARCH FOUNDATION, INC.

Grayson-Jockey Club Research Foundation is exempt from Federal income tax under section 501 (c) (3) of the Internal Revenue Code of 1986 (the "Code") as an organization operated exclusively for educational and scientific purposes. Contributions made to the Foundation are deductible by donors in computing their taxable income in the manner and to the extent provided by section 170 of the Code. Bequests, legacies, devices or transfers are deductible in computing the value of the taxable estate of a decedent for Federal estate tax purposes in the manner and to the extent provided by section 2055 of the Code. Gifts of property are deductible in computing taxable gifts for Federal gift tax purposes in the manner and to the extent provided by section 2522 of the Code. Provisions to approximately the same effect appear in the tax laws of most states. Grayson has shone in defining and refining our understanding of many diseases as the technology to image them has come on line.

---Dr. Larry Bramlage





GRAYSON-JOCKEY CLUB RESEARCH FOUNDATION, INC.

821 Corporate Drive, Lexington, KY 40503 (859) 224-2850 • Fax: (859) 224-2853

40 East 52nd Street, New York, NY 10022 (212) 371-5970 • Fax: (212) 371-6123

www.grayson-jockeyclub.org email: contactus@grayson-jockeyclub.org

